D Lamontagne

Summary

Country: Canada

Publications

  1. ncbi request reprint The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia
    D Lamontagne
    Faculte de Pharmacie, Universite de Montreal, QC, Canada
    Arch Mal Coeur Vaiss 99:242-6. 2006
  2. ncbi request reprint The metabolism of bradykinin: a cornerstone for the understanding of the cardiovascular effects of metallopeptidase inhibitors
    A Adam
    Universite de Montreal, Montreal, Canada
    Can J Cardiol 17:11A-4A. 2001
  3. pmc Seasonal congestive heart failure mortality and hospitalisation trends, Quebec 1990-1998
    D Ehrmann Feldman
    Direction de la Santé Publique de Montréal Centre, and Université de Montréal, GRIS et Ecole de réadaption, Quebec, Canada
    J Epidemiol Community Health 58:129-30. 2004
  4. pmc Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide
    C Lagneux
    , , CP 6128, Succursale Centre Ville, , , Canada, H3C 3J7
    Br J Pharmacol 132:793-6. 2001
  5. ncbi request reprint Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level
    M J Dumoulin
    , , 2900 Boul. Edouard-Montpetit, C.P. 6128, Succursale Centre-Ville, , , H3C 3J7, Canada
    Curr Hypertens Rep 3:S28-30. 2001
  6. ncbi request reprint CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart
    V Bodart
    Faculty of Pharmacy and Department of Pharmacology, Universite de Montreal, Montreal, Canada
    Circ Res 90:844-9. 2002
  7. pmc Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs
    N Nakhostine
    Department of Physiology, Faculty of Medicine, , , Canada
    Br J Pharmacol 110:71-6. 1993
  8. ncbi request reprint [Role of B1 receptors in the endothelial protective effect of ischaemic preconditioning]
    J F Bouchard
    , , , Canada
    Arch Mal Coeur Vaiss 91:941-5. 1998
  9. ncbi request reprint [Cardiac and vascular effects of cannabinoids: toward a therapeutic use?]
    C Ribuot
    Laboratoire HP2, Faculte de Pharmacie, Universite Grenoble I, Domaine de la Merci, 38706 La Tronche, France
    Ann Cardiol Angeiol (Paris) 54:89-96. 2005

Collaborators

  • A Adam
  • E J Beck
  • C Ribuot
  • R Couture
  • D Ehrmann Feldman
  • V Bodart
  • M J Dumoulin
  • C Lagneux
  • J F Bouchard
  • M Frenette
  • V Déry
  • C Kapetanakis
  • R Platt
  • N Giannetti
  • A Ducharme
  • A Perreault
  • P Pohankova
  • E Escher
  • H Ong
  • R L Silverstein
  • A Demers
  • T Sejlitz
  • M Febbraio
  • N McNicoll
  • G Molinaro
  • J Chouinard
  • N Nakhostine
  • R Nadeau

Detail Information

Publications9

  1. ncbi request reprint The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia
    D Lamontagne
    Faculte de Pharmacie, Universite de Montreal, QC, Canada
    Arch Mal Coeur Vaiss 99:242-6. 2006
    ..This latter effect appears to be mediated through CB2-receptors. Thus, the endogenous cardiac cannabinoid system, through activation of CB2-receptors, appears to be an important mechanism of protection against myocardial ischemia...
  2. ncbi request reprint The metabolism of bradykinin: a cornerstone for the understanding of the cardiovascular effects of metallopeptidase inhibitors
    A Adam
    Universite de Montreal, Montreal, Canada
    Can J Cardiol 17:11A-4A. 2001
    ..These studies advance understanding of the role of endogenous BK in the cardiovascular effects of ACE inhibitors and other metallopeptidase inhibitors...
  3. pmc Seasonal congestive heart failure mortality and hospitalisation trends, Quebec 1990-1998
    D Ehrmann Feldman
    Direction de la Santé Publique de Montréal Centre, and Université de Montréal, GRIS et Ecole de réadaption, Quebec, Canada
    J Epidemiol Community Health 58:129-30. 2004
    ..To describe seasonal congestive heart failure (CHF) mortality and hospitalisations in Quebec, Canada between 1990-1998 and compare trends in CHF mortality and morbidity with those in France...
  4. pmc Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide
    C Lagneux
    , , CP 6128, Succursale Centre Ville, , , Canada, H3C 3J7
    Br J Pharmacol 132:793-6. 2001
    ..Our results suggest an involvement of endocannabinoids, acting through the CB2 receptors, in the cardioprotection triggered by LPS against myocardial ischaemia. This could be attributed to a relationship between cannabinoids and NO...
  5. ncbi request reprint Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level
    M J Dumoulin
    , , 2900 Boul. Edouard-Montpetit, C.P. 6128, Succursale Centre-Ville, , , H3C 3J7, Canada
    Curr Hypertens Rep 3:S28-30. 2001
    ....
  6. ncbi request reprint CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart
    V Bodart
    Faculty of Pharmacy and Department of Pharmacology, Universite de Montreal, Montreal, Canada
    Circ Res 90:844-9. 2002
    ..These data suggest that CD36 may mediate the coronary vasospasm seen in hypercholesterolemia and atherosclerosis...
  7. pmc Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs
    N Nakhostine
    Department of Physiology, Faculty of Medicine, , , Canada
    Br J Pharmacol 110:71-6. 1993
    ..These findings provide pharmacological evidence for the existence of functionally active B1 receptors in canine cardiovascular homeostasis...
  8. ncbi request reprint [Role of B1 receptors in the endothelial protective effect of ischaemic preconditioning]
    J F Bouchard
    , , , Canada
    Arch Mal Coeur Vaiss 91:941-5. 1998
    ..B2 receptors do not play any role in that protection...
  9. ncbi request reprint [Cardiac and vascular effects of cannabinoids: toward a therapeutic use?]
    C Ribuot
    Laboratoire HP2, Faculte de Pharmacie, Universite Grenoble I, Domaine de la Merci, 38706 La Tronche, France
    Ann Cardiol Angeiol (Paris) 54:89-96. 2005
    ..However, the clinical use of cannabinoid receptors agonists or antagonists will depend on the development of non psychoactive compounds...